WO2022038479 - TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS
National phase entry:
Publication Number
WO/2022/038479
Publication Date
24.02.2022
International Application No.
PCT/IB2021/057483
International Filing Date
13.08.2021
Title **
[English]
TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS
[French]
FORMULATIONS PHARMACEUTIQUES TRANSDERMIQUES DE CANNABINOÏDES
Applicants **
PIKE THERAPEUTICS, INC.
Inventors
PLAKOGIANNIS, Fotios M.
MODI, Nisarg
Priority Data
63/066,386
17.08.2020
US
63/229,021
03.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4091 | |
| EPO | Filing, Examination, Granting | 55940 | |
| Japan | Filing, Examination, Granting | 3927 | |
| South Korea | Filing, Examination, Granting | 6007 | |
| USA | Filing, Examination, Granting | 17540 |
Total:
87,505
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to the transdermal administration of nabilone and cannabinoids and derivatives of these compounds, for the treatment and/or prevention and/or control of medical conditions.[French]
La présente divulgation concerne l'administration transdermique de nabilone et de cannabinoïdes et de dérivés de ces composés, pour le traitement et/ou la prévention et/ou le contrôle d'états médicaux.